Sutro Biopharma (STRO) Cash from Financing Activities (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Cash from Financing Activities data on file, last reported at -$64000.0 in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities fell 166.67% year-over-year to -$64000.0; the trailing twelve-month figure through Dec 2025 stood at $44000.0 (down 99.95% YoY), and the FY2025 full-year result was $44000.0, down 99.95% from the prior year.
• Cash from Financing Activities retreated to -$64000.0 in Q4 2025, from $102000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $137.7 million in Q2 2023 to a low of -$5.7 million in Q3 2023.
• A 5-year average of $14.2 million and a median of $633000.0 in 2021 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 14164.1% in 2022 and sank 166.67% in 2025, its largest moves.
• Tracing STRO's Cash from Financing Activities over 5 years: stood at $506000.0 in 2021, then jumped by 2315.22% to $12.2 million in 2022, then tumbled by 125.57% to -$3.1 million in 2023, then soared by 99.23% to -$24000.0 in 2024, then sank by 166.67% to -$64000.0 in 2025.
• Business Quant data shows STRO's Cash from Financing Activities at -$64000.0 in Q4 2025, $102000.0 in Q3 2025, and -$60000.0 in Q2 2025.